KALA BIO, Inc. made a presentation on Innovation In Ophthalmology and announced their target to report safety and efficacy data from their Phase 2b clinical trial by the end of 2024.
AI Assistant
KALA BIO INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.